Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and four issued foreign patents, as well as 15 U.S. and 49 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations.